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To the Editor,
The effective inhibition of unwanted human hair growth by safe and well-tolerated topical agents remains a major drawback of clinical and cosmetic dermatological treatments (Somani and Turvy 2014) . One key challenge is to promote hair follicle (HF) regression (catagen) with negligible skin toxicity or irritation (S1). Pilot evidence suggests that nicotinamide, an amide form of vitamin B3 (Forbat et al. 2017) , may be capable of doing this. That nicotinamide is used as a cosmetic and a dermatotherapeutic agent (Chen et al. 2016; Forbat et al. 2017; Niren 2006) (Supplementary Text ST1a) (Niren 2006; Walocko et al. 2017; S2) makes it an attractive candidate for hair growth inhibition. Therefore, we have investigated the hypothesis that nicotinamide may be an effective hair growth-inhibitor.
Micro-dissected human scalp HFs were obtained with institutional approval and written informed patient consent (Langan et al. 2015) . These were cultured in the presence of 200 µM or 10 mM (Supplementary text ST1b) nicotinamide for 6 days, and key human hair biology read-out parameters were assessed (Kloepper et al. 2010; Ramot et al. 2014 ).
HFs treated with nicotinamide (10 mM) showed significantly decreased hair shaft production ( Figure 1a ) and entered catagen more rapidly than vehicle control HFs (Figure 1b , example staging Figure S1 ). This was confirmed by double-immunohistomorphometry (Ki-67/TUNEL), which showed significantly decreased hair matrix keratinocyte proliferation (Ki-67) below Auber's line (AL), increased apoptosis (TUNEL) within the hair matrix in anagenphase HFs, showing a hair cycle independent effect of nicotinamide, (Figure 1c, d) , with no effect on HF melanin content ( Figure S2 , Supplementary text ST1).
As nicotinamide added to culture medium imitates "systemic" application, we next asked if topical application to organ cultured human scalp skin (Supplementary Text ST2) (Lu et al. 2007 ) also inhibited human hair growth. Results showed that HFs treated with topical Comparing this to skin organ culture, no significant change in MC degranulation resulted from 1% nicotinamide-hydrosome applied topically, though a significant increase by 4% nicotinamide-hydrosome was detected (Figure 2g, h) . Comparatively, nicotinamide-PEG6000 induced degranulation at a concentration of 1% (Figure 2i ) suggesting a hydrosome vehicle may have some ability to reduce degranulation when used in combination with lower concentrations of nicotinamide (Discussion point Supplementary ST1f).
To further probe skin inflammation by topical nicotinamide, the number of CD68+ dermal macrophages was also investigated finding a significant decrease by 4% nicotinamidehydrosome with a trend towards decreased numbers by 1% ( Figure S4c, g ). This suggests that nicotinamide does not induce lymphocytic inflammation but may induce itch and/or neurogenic inflammation. For this reason, a method for reducing MC degranulation whilst maintaining hair growth inhibition was examined.
For this purpose, palmitoylethanolamide (PEA, 30µM), an anti-pruritic endocannabinoid used in clinical dermatology, was applied to our nicotinamide/PEG6000 formulation (Supplementary text ST1b,c) and applied topically to ex vivo scalp sin to reduce MC degranulation (Parrella et al. 2016, S7) .
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The addition of PEA significantly reduced nicotinamide-induced dermal MC degranulation ex vivo (Figure 2i ) without altering the hair growth inhibitory effect (Figure 2j ). This supports the addition of PEA to future nicotinamide products to reduce MC degranulation-associated itch/inflammation while maintaining hair growth-inhibition (Supplementary text ST1d).
To examine the potential for topical nicotinamide-hydrosome (1% and 4%) formulations to cause additional epidermal side-effects which would render them unsuitable as a hair growthinhibitory products (Cerchia and Lavecchia 2017) , epidermal proliferation, apoptosis and pigmentation was assessed by quantitative immunohistomorphometry (Ki-67/TUNEL/Masson-Fontana). Neither 1% or 4% topical nicotinamide-hydrosome formulation significantly altered epidermal proliferation, apoptosis or pigmentation ( Figure   S4A ,B, D-F) (supplementary text ST1e for discussion point).
Taken together these data present clear evidence that nicotinamide can effectively inhibit human hair growth and promote catagen in our clinically relevant models. That this occurred at commercially/clinically relevant concentrations without negatively affecting epidermal vitality or pigmentation makes nicotinamide an excellent cosmeceutical hair growth inhibitor for subsequent clinical testing. Data also suggest that hydrosomes provide a suitable vehicle and that PEA addition may reduce any potential skin irritation/itch that might be seen after repetitive application in vivo.
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